Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy

Oncology Letters

Volumn 8, Issue 2, 2014, Pages 845-848

  Gezer, Ugur ^a   Keskin, Serkan ^a   Iǧci, Abdullah ^a   Tükenmez, Mustafa ^a   Tiryakioǧlu, Duygu ^a   Çetinkaya, Merve ^a   Dişci, Rian ^a   Dalay, Nejat ^a   Eralp, Yeşim ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Circulating microRNAs; Neoadjuvant chemotherapy

Indexed keywords

COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; EPIRUBICIN; MICRORNA; MICRORNA 10B; MICRORNA 155; MICRORNA 195; MICRORNA 200C; MICRORNA 205; MICRORNA 21; MICRORNA 221; MICRORNA 34; MICRORNA LET7; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; MRNA EXPRESSION ASSAY; POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; TUMOR VOLUME; UPREGULATION;

EID: 84902314818     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2188     Document Type: Article

References (21)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
3. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398, 2003.
4. Sotiriou C and Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med 360: 790-800, 2009.
5. Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70, 2012.
6. Moulder S: Intrinsic resistance to chemotherapy in breast cancer. Womens Health (Lond Engl) 6: 821-830, 2010.
7. Sun Y, Wang M, Lin G, et al: Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One 7: e47003, 2012.
8. Braicu C, Calin GA and Berindan-Neagoe I: MicroRNAs and cancer therapy-from bystanders to major players. Curr Med Chem 20: 3561-3573, 2013.
9. Harquail J, Benzina S and Robichaud GA: MicroRNAs and breast cancer malignancy: an overview of miRNA-regulated cancer processes leading to metastasis. Cancer Biomark 11: 269-280, 2012.
10. Madhavan D, Cuk K, Burwinkel B and Yang R: Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet 4: 116, 2013.
11. Cuk K, Zucknick M, Heil J, et al: Circulating microRNAs in plasma as early detection markers for breast cancer. Int J Cancer 132: 1602-1612, 2013.
12. Zhao R, Wu J, Jia W, et al: Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie 34: 675-680, 2011.
13. Jung EJ, Santarpia L, Kim J, et al: Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer 118: 2603-2614, 2012.
14. Wang H, Tan G, Dong L, et al: Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One 7: e34210, 2012.
15. Liu H: MicroRNAs in breast cancer initiation and progression. Cell Mol Life Sci 69: 3587-3599, 2012.
16. Heneghan HM, Miller N, Kelly R, Newell J and Kerin MJ: Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 15: 673-682, 2010.
17. Kumar S, Keerthana R, Pazhanimuthu A and Perumal P: Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients. Indian J Biochem Biophys 50: 210-214, 2013.
18. Chen J, Wang BC and Tang JH: Clinical significance of microRNA-155 expression in human breast cancer. J Surg Oncol 106: 260-266, 2012.
19. Zhao Y, Deng C, Wang J, et al: Let-7 family miRNAs regulate estrogen receptor alpha signaling in estrogen receptor positive breast cancer. Breast Cancer Res Treat 127: 69-80, 2011.
20. Sun X, Qin S, Fan C, et al: Let-7: a regulator of the ERα signaling pathway in human breast tumors and breast cancer stem cells. Oncol Rep 29: 2079-2087, 2013.
21. Zhao G, Cai C, Yang T, et al: MicroRNA-221 induces cell survival and cisplatin resistance through PI3K/Akt pathway in human osteosarcoma. PloS One 8: e53906, 2013.